197 related articles for article (PubMed ID: 31452019)
21. Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Rami-Porta R; Asamura H; Travis WD; Rusch VW
CA Cancer J Clin; 2017 Mar; 67(2):138-155. PubMed ID: 28140453
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcomes of thoracic radiotherapy for locally advanced NSCLC with EGFR mutations or EML4-ALK rearrangement.
Hayashi H; Okamoto I; Kimura H; Sakai K; Nishimura Y; Nishio K; Nakagawa K
Anticancer Res; 2012 Oct; 32(10):4533-7. PubMed ID: 23060582
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
[TBL] [Abstract][Full Text] [Related]
24. Effect of epidermal growth factor receptor mutation on early-stage non-small cell lung cancer according to the 8th TNM classification.
Isaka T; Ito H; Nakayama H; Yokose T; Yamada K; Masuda M
Lung Cancer; 2020 Jul; 145():111-118. PubMed ID: 32428800
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Aiko N; Shimokawa T; Miyazaki K; Misumi Y; Agemi Y; Ishii M; Nakamura Y; Yamanaka T; Okamoto H
BMC Cancer; 2018 Oct; 18(1):1012. PubMed ID: 30348116
[TBL] [Abstract][Full Text] [Related]
26. Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden.
Tendler S; Grozman V; Lewensohn R; Tsakonas G; Viktorsson K; De Petris L
Lung Cancer; 2018 Jun; 120():75-81. PubMed ID: 29748020
[TBL] [Abstract][Full Text] [Related]
27. Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?
Wang TJ; Saad S; Qureshi YH; Jani A; Nanda T; Yaeh AM; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Lesser J; Halmos B; Stoopler MB; Lassman AB; Cheng SK; Isaacson SR
Neuro Oncol; 2015 Jul; 17(7):1022-8. PubMed ID: 25910841
[TBL] [Abstract][Full Text] [Related]
28. Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages.
Zhou JX; Yang H; Deng Q; Gu X; He P; Lin Y; Zhao M; Jiang J; Chen H; Lin Y; Yin W; Mo L; He J
Ann Oncol; 2013 May; 24(5):1319-25. PubMed ID: 23277484
[TBL] [Abstract][Full Text] [Related]
29. [Prognostic value of AJCC TNM Staging 7th edition in limited-stage small cell lung cancer: validation in 437 patients].
Zhang W; Zhu H; Zhou Z; Feng Q; Chen D; Zhang H; Xiao Z; Wang L
Zhonghua Zhong Liu Za Zhi; 2015 Dec; 37(12):917-22. PubMed ID: 26887621
[TBL] [Abstract][Full Text] [Related]
30. Staging Lung Cancer: Metastasis.
Shroff GS; Viswanathan C; Carter BW; Benveniste MF; Truong MT; Sabloff BS
Radiol Clin North Am; 2018 May; 56(3):411-418. PubMed ID: 29622076
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
[TBL] [Abstract][Full Text] [Related]
32. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
[TBL] [Abstract][Full Text] [Related]
33. Serum carcinoembryonic antigen levels before initial treatment are associated with EGFR mutations and EML4- ALK fusion gene in lung adenocarcinoma patients.
Wang WT; Li Y; Ma J; Chen XB; Qin JJ
Asian Pac J Cancer Prev; 2014; 15(9):3927-32. PubMed ID: 24935562
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.
Boros A; Lacroix L; Lacas B; Adam J; Pignon JP; Caramella C; Planchard D; de Montpreville V; Deutsch E; Levy A; Besse B; Le Pechoux C
Oncotarget; 2017 Apr; 8(15):25189-25199. PubMed ID: 28445990
[TBL] [Abstract][Full Text] [Related]
35. [Research progress in non-small cell lung cancer with concomitant EML4-ALK fusion gene and EGFR gene mutation].
Zeng Z; Wu Y
Zhongguo Fei Ai Za Zhi; 2011 Nov; 14(11):880-4. PubMed ID: 22104224
[TBL] [Abstract][Full Text] [Related]
36. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
[TBL] [Abstract][Full Text] [Related]
37. Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan.
Yoshida H; Kim YH; Iwatsubo S; Sakaguchi C; Sakamori Y; Nagai H; Ozasa H; Mio T; Hirai T
Oncology; 2020; 98(7):460-467. PubMed ID: 32222702
[TBL] [Abstract][Full Text] [Related]
38. The new 8th TNM staging system of lung cancer and its potential imaging interpretation pitfalls and limitations with CT image demonstrations.
Feng SH; Yang ST
Diagn Interv Radiol; 2019 Jul; 25(4):270-279. PubMed ID: 31295144
[TBL] [Abstract][Full Text] [Related]
39. A hypothesized TNM staging system based on the number and location of positive lymph nodes may better reflect the prognosis for patients with NSCLC.
Shang X; Liu J; Li Z; Lin J; Wang H
BMC Cancer; 2019 Jun; 19(1):591. PubMed ID: 31208403
[TBL] [Abstract][Full Text] [Related]
40. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]